Shanghai Best-link Bioscience, Llc

This early-phase study tests a new drug (BL0020) combined with an immunotherapy (Toripalimab) in about 33 adults with extensive-stage small cell lung cancer that returned after first treatment. The main goals are to find a safe dose and see if the combo can shrink tumors. This is…

This study tests a new drug, BL0020, in 48 people whose lung cancer changed from one type to a more aggressive small cell form after initial treatment. The goal is to see if the drug can shrink tumors and control the disease. Participants must have this specific cancer transforma…

This early-phase study tests a single dose of a new drug called BL0175 in 27 postmenopausal women. The main goal is to check for side effects and see how long the drug stays in the blood, comparing it to an existing drug, fulvestrant. Participants will receive either BL0175 or fu…